Nervgen Pharma (NGEN) Total Non-Current Liabilities (2024)
Nervgen Pharma (NGEN) posted quarterly Total Non-Current Liabilities of $5990.9 for Q4 2024.
Nervgen Pharma (NGEN) Total Non-Current Liabilities (2024) Analysis & Trends
Nervgen Pharma (NGEN) has reported Total Non-Current Liabilities for 1 consecutive years, with $5990.9 the latest figure, recorded in Q4 2024.
- In Q4 2024, Total Non-Current Liabilities changed N/A year-over-year to $5990.9; the TTM figure through Dec 2024 stood at $5990.9 (changed N/A YoY), while the FY2024 annual figure was $5990.9, changed N/A from the prior year.
- Total Non-Current Liabilities steadied at $5990.9 in Q4 2024 per NGEN's latest filing.
- Across five years, Total Non-Current Liabilities topped out at $5990.9 in Q4 2024 and bottomed at $5990.9 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 9.32 Bn |
| 10 | Nervgen Pharma | 163.63 Mn | 163.63 Mn | - | 15.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5,990.94 |